The role of the Kras4A isoform in epithelial carcinogenesis
The role of the Kras4A isoform in epithelial carcinogenesis
批准号:
8373745
负责人:
ALLAN BALMAIN
金额:
$26.97万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2017-06-30
关键词:
AccountingAffectAlveolarAnimalsAutomobile DrivingBiochemicalCancer EtiologyCell membraneCellsCessation of lifeChemical AgentsChromosomes, Human, Pair 6CodeCollaborationsColonDefectDevelopmentDimerizationDown-RegulationDrug Delivery SystemsEmbryoEpithelialEpitheliumExposure toFamily memberFibroblastsGene ExpressionGenesGenetically Engineered MouseGenotypeGoalsHumanImageImaging technologyIn VitroKRAS2 geneLaboratoriesLightLocationLungLung NeoplasmsMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMediatingMicroscopyMinorModelingMusMutateMutationNatural regenerationNormal tissue morphologyOncogene ProteinsPIK3CG genePancreatic carcinomaPathway AnalysisPathway interactionsPatientsPlayPredispositionPropertyProtein IsoformsProteinsRAS Family GeneRNA SplicingRas Signaling PathwayRelative (related person)ResistanceRoleSignal PathwaySignal TransductionSkinSkin NeoplasmsStem cellsSystemTestingTetracyclinesTherapeuticTissuesVariantWorkcancer stem cellcarcinogenesisin vivomouse modelmutantnew technologynovelnovel strategiesphotoactivationpromotersingle moleculesmall hairpin RNAstem cell populationtissue regenerationtooltumortumor initiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Genes of the RAS family were found to be mutated in human cancers around 30 years ago, and the long term goal of this project is to develop a deeper understanding of the mechanisms by which these genes cause malignant transformation. The KRAS gene is the most commonly mutated family member, particularly in carcinomas of the pancreas, colon and lung. Together, these tumors account for hundreds of thousands of deaths worldwide each year. Using genetically engineered mouse models, this laboratory showed that a minor isoform of Kras (Kras4A) is essential for development of Kras mutant tumors. Mice deficient in this isoform are highly resistant to development of lung or skin tumors with Kras mutations, suggesting that inhibition of the function of Kras4A could result in therapeutic benefit for patients. This project involves a comprehensive analysis of the signaling pathway that is activated by this specific form of the Kras protein. A number of novel approaches will be used to understand how Kras4A signals within cells and tissues. A recently developed new imaging approach (Photo-activated localization microscopy, or PALM) will image the location of single molecules of Kras4A in cells, and find out whether there is an interaction between mutant and wild type Kras4A proteins. Signaling through canonical RAS pathway components in cells lacking Kras4A or both Kras4A and 4B, will be investigated in order to identify any specific signaling pathways that are deficient in these cells. Finally, an unbiased view of Kras signaling in vivo in mouse lungs will be developed, using novel gene expression network analysis tools. Comparison of gene expression networks from mice that are susceptible to lung cancer with those that are resistant due to deletion of Kras4A may identify pathways not previously associated with Ras that may account for the critical role of Kras4A in transformation. Using mouse models in vivo, the possible function of Kras4A in regeneration of lung epithelium from stem cells after damage will be studied, and new models in which Kras4A can be inhibited using inducible shRNA will be developed to investigate the role of this protein in the propagation and maintenance of tumors with mutant Kras genes.
PUBLIC HEALTH RELEVANCE: Cancers are caused by mutations in genes, and one of the most commonly mutated genes is known as KRAS. These specific mutations are found in hundreds of thousands of tumors each year, and the goal of this project is to find new ways to treat these cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROMINENT - UCSF
-
批准号:10845756
-
项目类别:
-
资助金额:$120.79万
-
财政年份:2022
-
负责人:ALLAN BALMAIN
-
依托单位:
PROMINENT - UCSF
-
批准号:10625150
-
项目类别:
-
资助金额:$126.44万
-
财政年份:2022
-
负责人:ALLAN BALMAIN
-
依托单位:
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
-
批准号:10199951
-
项目类别:
-
资助金额:$101.04万
-
财政年份:2017
-
负责人:ALLAN BALMAIN
-
依托单位:
Systems genetics analysis of tumor evolution in the mouse
-
批准号:10621723
-
项目类别:
-
资助金额:$93.2万
-
财政年份:2017
-
负责人:ALLAN BALMAIN
-
依托单位:
Systems genetics analysis of tumor evolution in the mouse
-
批准号:10394264
-
项目类别:
-
资助金额:$93.2万
-
财政年份:2017
-
负责人:ALLAN BALMAIN
-
依托单位:
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
-
批准号:9767561
-
项目类别:
-
资助金额:$98.01万
-
财政年份:2017
-
负责人:ALLAN BALMAIN
-
依托单位:
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
-
批准号:9363115
-
项目类别:
-
资助金额:$106.56万
-
财政年份:2017
-
负责人:ALLAN BALMAIN
-
依托单位:
The Oncogenic and Tumor Suppressor Functions of the Kras isoform 4A in vivo
-
批准号:8672543
-
项目类别:
-
资助金额:$45.86万
-
财政年份:2015
-
负责人:ALLAN BALMAIN
-
依托单位:
The Oncogenic and Tumor Suppressor Functions of the Kras isoform 4A in vivo
-
批准号:9058497
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2015
-
负责人:ALLAN BALMAIN
-
依托单位:
Genetic analysis of ras mutation specificity in skin and lung cancer
-
批准号:9191353
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2015
-
负责人:ALLAN BALMAIN
-
依托单位:
Science Leadership and Integration
-
批准号:7923790
-
项目类别:
-
资助金额:$73.66万
-
财政年份:2009
-
负责人:ALLAN BALMAIN
-
依托单位:
Science Leadership and Integration
-
批准号:8546987
-
项目类别:
-
资助金额:$60.82万
-
财政年份:2009
-
负责人:ALLAN BALMAIN
-
依托单位:
Science Leadership and Integration
-
批准号:7740568
-
项目类别:
-
资助金额:$49.92万
-
财政年份:2009
-
负责人:ALLAN BALMAIN
-
依托单位:
Science Leadership and Integration
-
批准号:8331870
-
项目类别:
-
资助金额:$67.43万
-
财政年份:2009
-
负责人:ALLAN BALMAIN
-
依托单位:
Science Leadership and Integration
-
批准号:8142902
-
项目类别:
-
资助金额:$69.3万
-
财政年份:2009
-
负责人:ALLAN BALMAIN
-
依托单位:
GENOME ANALYSIS
-
批准号:7506489
-
项目类别:
-
资助金额:$24.46万
-
财政年份:2007
-
负责人:ALLAN BALMAIN
-
依托单位:
Sequenom MassArray System
-
批准号:7213490
-
项目类别:
-
资助金额:$47.03万
-
财政年份:2007
-
负责人:ALLAN BALMAIN
-
依托单位:
The role of Kras2 in lung tumor susceptibility
-
批准号:7099015
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2006
-
负责人:ALLAN BALMAIN
-
依托单位:
The role of the Kras4A isoform in epithelial carcinogenesis
-
批准号:8545677
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2006
-
负责人:ALLAN BALMAIN
-
依托单位:
The role of Kras2 in lung tumor susceptibility
-
批准号:7215137
-
项目类别:
-
资助金额:$26.52万
-
财政年份:2006
-
负责人:ALLAN BALMAIN
-
依托单位:
海外基金